Codexis, Inc (NASDAQ:CDXS) Unveils Its Financial Results For The Year Ended 2017
Codexis, Inc (NASDAQ:CDXS) has proceeded to announce its 2017 financial results for the three and 12
Continue reading >All posts in "Biotech"
Shares Of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Sink After The Failure Of A New Study
The shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) declined by about 33% and that followed a recent
Continue reading >Crispr Therapeutics AG (NASDAQ:CRSP) Presents Positive Data In Line With The CAR-T Cell Therapies
The stock of Crispr Therapeutics AG (NASDAQ:CRSP) closed at $51.18 losing 1.14% in yesterday’s trading
Continue reading >NuCana PLC (ADR) (NASDAQ:NCNA) Appoints Adam George As Chairman Of Audit Committee
NuCana PLC (ADR) (NASDAQ:NCNA) announced recently that it has appointed Adam George as the new member
Continue reading >Fennec Pharmaceuticals Inc (NASDAQ:FENC) Receives Breakthrough Therapy Designation
Fennec Pharmaceuticals Inc (NASDAQ:FENC) announced recently that the US Food and Drug Administration
Continue reading >Marrone Bio Innovations Inc (NASDAQ:MBII) Stocks Spike After A Research Firm’s ‘Decent Pick’ Recommendation
Marrone Bio Innovations Inc (NASDAQ:MBII) shares rose 21.7% last week after Zacks Equity Research recommended
Continue reading >Codexis, Inc. (NASDAQ:CDXS) Appoints Shawn Clairmont As Senior Director Prior To Making Presentation At A Science Corporation
Codexis, Inc. (NASDAQ:CDXS) recently appointed Shawn Clairmont as the Senior Director, Molecular Diagnostics
Continue reading >Sellas Life Sciences Group Inc (NASDAQ:SLS) Positive Phase 2 Breast Cancer Trial Data Send Stocks Skyrocketing
Sellas Life Sciences Group Inc (NASDAQ:SLS) shares skyrocketed after the successful Phase 2 interim
Continue reading >Innovate Biopharmaceuticals Inc (NASDAQ:INNT) Brings Onboard June Almenoff As Its New CEO
Innovate Biopharmaceuticals Inc (NASDAQ:INNT) today proceeded to name its newly appointed Chief Operating
Continue reading >KemPharm Inc (NASDAQ:KMPH) Unleashes Fourth Quarter And Year End Corporate And Financial Results
The stock of KemPharm Inc (NASDAQ:KMPH) closed at $6.55 losing 3.68% in yesterday’s trading session.
Continue reading > Page 1 of 17
